Investors Back Asceneuron To Rival Lilly In Alzheimer’s Oral Drug Class

 
• By Andrew McConaghie
  
Tau Alzheimer's disease
Pathological phosphorylation of Tau proteins leads to disintegration of microtubuli in an axon and to aggregation of the tau proteins. • Source: Shutterstock

More from Business

More from Scrip